SELLAS Life Sciences Group, Inc. (SLS)
11.74
+0.41
(+3.62%)
USD |
NASDAQ |
Oct 02, 16:00
11.75
+0.01
(+0.09%)
After-Hours: 20:00
SELLAS Life Sciences Group Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2022 | 85.50% |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | 94.74% |
| March 31, 2021 | 83.40% |
| December 31, 2020 | 95.95% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | 73.09% |
| March 31, 2015 | 80.40% |
| December 31, 2014 | 79.37% |
| September 30, 2014 | 80.43% |
| June 30, 2014 | 80.91% |
| March 31, 2014 | 80.58% |
| December 31, 2013 | 73.42% |
| September 30, 2013 | 74.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 74.71% |
| Capricor Therapeutics, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Incyte Corp. | 92.57% |
| Insmed, Inc. | 83.71% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -41.86% |
| Return on Assets | -38.48% |
| Return on Invested Capital | -41.44% |
| Return on Net Operating Assets | -497.5% |